Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
600 PATIENTS RANDOMIZED!!!
Congratulations to Dr. Willibald Schroeder and the team at GYNAEKOLOGICUM Bremen, Germany for enrolling the 600th patient to the SHAPE study! On behalf of the SHAPE trial committee, we would like to thank you for your tremendous and unwavering support of our trial. The countdown is on....let's see the SHAPE trial reach its accrual goal by the end of 2019!
HN10, A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma, is centrally activated.
The CCTG Annual Spring Meeting of Participants is almost here, if you are planning meetings and/or attending the Spring Meeting please read the information below:
The Supportive Care Committee and Lung Disease Site are actively seeking a CRA representative volunteer from our Canadian centres.
A Canadian Cancer Trials Group update regarding the Protection of Human Research Participant Training
In September 2018, the NIH Office of Extramural Research (OER) released that the current free Protecting Human Research Participant (PHRP) training course would no longer be offered and neither would an alternative. In alignment with the NIH, CCTG confirmed that the CITI Human Subjects Research Course is an acceptable option for Human Subjects Protection training as well as training courses developed and administered at the institutional level.
The IND234 clinical trial, conducted by the Canadian Cancer Trials Group (CCTG), uses liquid biopsy technology to screen for genomic markers in prostate cancer patients.
After the liquid biopsy analysis, patients with specific DNA markers are assigned to one of five new therapies targeted at their unique form of prostate cancer. Researchers want to see if the markers identified in the screening process can help predict which patients will be helped the most by the targeted treatments.
Citations for two previously published CCTG trials are now available online.
